nimodipine
FDA Approved, EMA Approved
Description
Nimodipine is a dihydropyridine calcium channel blocker with preferential cerebrovascular effects. It is specifically indicated for improving neurological outcomes following aneurysmal subarachnoid hemorrhage by reducing cerebral vasospasm. The drug crosses the blood-brain barrier and has neuroprotective properties.
Indications & Therapeutic Use
aneurysmal subarachnoid hemorrhage, cerebral vasospasm prevention
Linked Diseases:
Global Availability (8 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
nimodipine
| Generic Name | nimodipine |
| Brands | 1 brand available |
| Active Ingredient | nimodipine |
| Drug Class | aneurysmal subarachnoid hemorrhage |
| Manufacturer | Bayer |
| Dosage Forms | oral capsule 30mg; oral solution 30mg/10mL |
| Medical Code | C08CA06 |
| Orphan Status | No |
| Cold Chain | Not Required |
| Lead Time | 5 days |
| Reg. Status | FDA Approved, EMA Approved |
| Clinical Trial | NCT00000544 |
| Countries | 8 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations9 Validated Nodes